Skip to main content

and
  1. Article

    Open Access

    Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression

    This open-label, Phase 1b/2 study evaluated the highly selective MET inhibitor tepotinib in systemic anticancer treatment (SACT)-naive Asian patients with advanced hepatocellular carcinoma (aHCC) with MET over...

    Baek-Yeol Ryoo, Ann-Li Cheng, Zhenggang Ren, Tae-You Kim in British Journal of Cancer (2021)

  2. Article

    Open Access

    Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial

    Association of immune-related adverse events with tumor response has been reported. Reactive cutaneous capillary endothelial proliferation (RCCEP) is the most common adverse event related to camrelizumab, an i...

    Feng Wang, Shukui Qin, **nchen Sun, Zhenggang Ren in Journal of Hematology & Oncology (2020)

  3. Article

    Open Access

    Higher matrix stiffness as an independent initiator triggers epithelial-mesenchymal transition and facilitates HCC metastasis

    Increased liver stiffness exerts a detrimental role in driving hepatocellular carcinoma (HCC) malignancy and progression, and indicates a high risk of unfavorable outcomes. However, it remains largely unknown ...

    Yinying Dong, Qiongdan Zheng, Zhiming Wang, **ahui Lin in Journal of Hematology & Oncology (2019)

  4. Article

    Open Access

    Matrix stiffness-upregulated LOXL2 promotes fibronectin production, MMP9 and CXCL12 expression and BMDCs recruitment to assist pre-metastatic niche formation

    Higher matrix stiffness affects biological behavior of tumor cells, regulates tumor-associated gene/miRNA expression and stemness characteristic, and contributes to tumor invasion and metastasis. However, the ...

    Sifan Wu, Qiongdan Zheng, **aoxia **ng in Journal of Experimental & Clinical Cancer … (2018)

  5. No Access

    Article

    Transarterial chemoembolization for huge hepatocellular carcinoma with diameter over ten centimeters: a large cohort study

    Patients with huge hepatocellular carcinoma >10 cm in diameter represent a special subgroup for treatment. To date, there are few data and little consensus on treatment strategies for huge hepatocellular carci...

    Tongchun Xue, Fan Le, Rongxin Chen, **aoying **e, Lan Zhang in Medical Oncology (2015)

  6. Article

    Open Access

    Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma

    Recently, a phase II clinical trial in hepatocellular carcinoma (HCC) has suggested that the combination of sorafenib and 5-fluorouracil (5-FU) is feasible and side effects are manageable. However, preclinical...

    Lifen Deng, Zhenggang Ren, Qingan Jia, Weizhong Wu, Hujia Shen, Yanhong Wang in BMC Cancer (2013)

  7. No Access

    Article

    Lipiodolized transarterial chemoembolization in hepatocellular carcinoma patients after curative resection

    To explore the effect of lipiodolized transarterial chemoembolization (lip-TACE) in hepatocellular carcinoma (HCC) patients at different risk of recurrence after curative resection.

    **aohong Chen, Boheng Zhang, **n Yin in Journal of Cancer Research and Clinical On… (2013)

  8. Article

    Open Access

    Identification of tyrosine-phosphorylated proteins associated with metastasis and functional analysis of FER in human hepatocellular carcinoma cells

    Aberrant activity of tyrosine-phosphorylated proteins is commonly associated with HCC metastasis. Cell signaling events driven by these proteins are implicated in numerous processes that alter cancer cell beha...

    Haiyu Li, Zhenggang Ren, **aonan Kang, Lan Zhang, Xuefei Li, Yan Wang in BMC Cancer (2009)

  9. No Access

    Article

    “Three-Grade Criteria” of radical resection for primary liver cancer

    The present study was designed to develop the “Three-Grade Criteria” for radical resection of primary liver cancer (PLC) and to evaluate its clinical significance.

    Zengchen Ma, Liwen Huang, Zhaoyou Tang, **nda Zhou in Chinese Journal of Clinical Oncology (2005)